Travere Therapeutics Is Maintained at Buy by Guggenheim
Ratings actions from Benzinga: GMT) Travere Therapeutics Price Target Raised to $89.00/Share From $75.00 by GuggenheimRatings actions from Benzinga
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.